Intracellular labile iron pools as direct targets of iron chelators: A fluorescence study of chelator action in living cells

Blood

Volumn 106, Issue 9, 2005, Pages 3242-3250

  Glickstein, Hava ^a   El, Rinat Ben ^a   Shvartsman, Maya ^a   Cabantchik, Z Ioav ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CALCEIN; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FLUORESCENT DYE; IRON; IRON CHELATING AGENT; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ARTICLE; CELL LINE; CELL ORGANELLE; CHELATION; CONTROLLED STUDY; CYTOSOL; DRUG MECHANISM; ENDOSOME; FLUORESCENCE; FLUORESCENCE MICROSCOPY; HEART MUSCLE CELL; HUMAN; HUMAN CELL; LIVER CELL; LYSOSOME; MACROPHAGE; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 27644539382     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-02-0460     Document Type: Article

References (45)

1. Hershko C, Link G , Konijn AM, Cabantchik ZI. Iron chelation therapy. Curr Hematol. 2005;4:110-116.
2. Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik ZI. Labile plasma iron in iron overload: redox activity and susceptibility to chelators. Blood. 2003;102:2670-2677.
3. Finch CA, Deubelbeiss K, Cook JD, et al. Ferrokinetics in man. Medicine (Baltimore). 1970;49:17-53.
4. Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. Hematology (Am Soc Hematol Educ Program). 2001:47-61.
5. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89:739-761.
6. Gabutti V, Borgna-Pignatti C. Clinical manifestations and therapy of transfusional haemosiderosis. Bailliere's Clin Haematology. 1994;7:919-940.
7. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and disease complications in thalassemia major. Ann N Y Acad Sci. 1998;850:227-231.
8. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous -thalassemia. N Eng J Med. 1994;331:574-578.
9. Modell B, Letsky EA, Flynn DM, et al. Survival and desferrioxamine in thalassaemia major. Brit Med J. 1982;284:1081-1084.
10. Davis BA, Porter JB. Results of long term iron chelation treatment with Deferoxamine. Adv Exp Med Biol. 2002;509:91-125.
11. Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica. 2003;88:489-496.
12. Hershko C, Cappellini MD, Galanello R, Piga A, Tognoni G, Masera G. Purging iron from the heart. Br J Haematol. 2003;125:545-551.
13. Liu ZD, Liu DY, Hider RC. Iron chelator chemistry. Adv Exp Med Biol. 2002;509:141-166.
14. Nick H, Acklin P, Lattmann R, et al. Development of tridentate iron chelators from desferrithiocin to ICL670. Curr Med Chem. 2003;10:1065-1076.
15. Hoyes KP, Porter JB. Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron pools. Br J Haematol. 1993;85:393-400.
16. Cabantchik ZI, Kakhlon O, Epsztejn S, Zanninelli G, Breuer W. Intracellular and extracellular labile iron pools. Adv Exp Med Biol. 2002;509:55-75.
17. Jacobs A. An intracellular transit iron pool. Blood. 1977;50:4331-4336.
18. Epsztejn S, Kakhlon O, Glickstein H, Breuer W, Cabantchik ZI. Fluorescence analysis of the labile iron pool of mammalian cells. Anal Biochem. 1997;248:31-40.
19. Zanninelli G, Glickstein H, Breuer W, et al. Chelation and mobilization of cellular iron by different classes of chelators. Mol Pharmacol. 1997;51:842-852.
20. Esposito BP, Epsztejn S, Breuer W, Cabantchik ZI. A review of fluorescence methods for assessing labile iron in cells and biological fluids. Anal Biochem. 2002;304:1-18.
21. Kakhlon O, Cabantchik ZI. The labile iron pool: characterization, measurement, and participation in cellular processes (1). Free Radic Biol Med. 2002;33:1037-1046.
22. Petrat F, de Groot H, Sustmann R, Rauen U. The chelatable iron pool in living cells: a methodically defined quantity. Biol Chem. 2002;383:489-502.
23. Petrat F, Weisheit D, Lensen M, de Groot H, Sustmann R, Rauen U. Selective determination of mitochondrial chelatable iron in viable cells with a new fluorescent sensor. Biochem J. 2002;362:137-147.
24. Tsien RY. Fluorescent probes of cell signaling. Ann Rev Neurosci. 1989;12:227-253.
25. Zhang AS, Sheftel AD, Ponka P. Intracellular kinetics of iron in reticulocytes: evidence for endosome involvement in iron targeting to mitochondria. Blood. 2005;105:368-375.
26. Doulias PT, Christoforidis S, Brunk UT, Galaris D. Endosomal and lysosomal effects of desferrioxamine: protection of HeLa cells from hydrogen peroxide-induced DNA damage and induction of cell-cycle arrest. Free Radic Biol Med. 2004;35:719-728.
27. Burckhardt BC, Burckhardt G. Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev Physiol Biochem Pharmacol. 2003;146:95-158.
28. Wrona M, Patel K, Wardman P. Reactivity of 2′,7′- dichlorodihydrofluorescein and dihydrorhodamine 123 and their oxidized forms toward carbonate, nitrogen dioxide, and hydroxyl radicals. Free Radic Biol Med. 2005;38:262-270.
29. Sankaran NB, Banthia S, Samanta S. Fluorescence signalling of the transition metal ions: design strategy based on the choice of the fluorophore component. Proc Indian Acad Sci (Chem Sci). 2002;114:539-545.
30. Cabantchik ZI, Epstejn S, Breuer W. Novel methods for assessing transport of iron across biological membranes. In: Templeton DM, ed. Cellular and Molecular Iron Transport. New York, NY: Marcel Dekker. 2001:353-383.
31. Ponka P, Borova J, Neuwirth J, Fuchs O, Necas E. A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents. Biochim Biophys Acta. 1979;586:278-297.
32. Richardson DR, Ponka P. Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease. J Lab Clin Med. 1998;131:306-314.
33. Rouault T, Klausner R. Regulation of iron metabolism in eukaryotes. Curr Top Cell Regul. 1997;35:1-19.
34. Eisenstein RS. Iron regulatory proteins and the molecular control of mammalian iron metabolism. Ann Rev Nutrition. 2001;20:627-662.
35. Petrat F, Paluch S, Dogruoz E, et al. Reduction of Fe(III) ions complexed to physiological ligands by lipoyl dehydrogenase and other flavoenzymes in vitro: implications for an enzymatic reduction of Fe(III) ions of the labile iron pool. J Biol Chem. 2003;278:46403-46413.
36. Napier I, Ponka P, Richardson DR. Iron trafficking in the mitochondrion: novel pathways revealed by disease. Blood. Prepublished on November 4, 2004, as DOI 10.1182/blood-2004-10-3856.
37. (Now available as Blood. 2005;105:1867-1874).
38. Breuer W, Epsztejn S, Cabantchik ZI. Iron acquired from transferrin by K562 cells is delivered into a cytoplasmic pool of chelatable iron(II). J Biol Chem. 1995;270:24209-24215.
39. Konijn AM, Glickstein H, Vaisman B, Meyron-Holtz EG, Slotki IN, Cabantchik ZI. The cellular labile iron pool and intracellular ferritin in K562 cells. Blood. 1999;94:2128-2134.
40. Cabantchik ZI, Glickstein H, Milgram P, Breuer W. A fluorescence assay for assessing chelation of intracellular iron in a membrane model system and in mammalian cells. Anal Biochem. 1996;233:221-227.
41. Cohen AR, Galanello R, Pennell DJ, Cunningham MJ, Vichinsky E. Thalassemia. Hematology (Am Soc Hematol Educ Program). 2004:14-34.
42. Hasinoff BB, Patel D, Wu X. The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin. Free Radic Biol Med. 2003;35:1469-1479.
43. Richardson DR, Mouralian C, Ponka P, Becker E. Development of potential iron chelators for the treatment of Friedreich's ataxia: ligands that mobilize mitochondrial iron. Biochim Biophys Acta. 2001;1536:133-140.
44. Richardson DR. Friedreich's ataxia: iron chelators that target the mitochondrion as a therapeutic strategy? Expert Opin Investig Drugs. 2003;12:235-245.
45. Richardson DR, Ponka P, Baker E. The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell. Cancer Res. 1994;54:685-689.